Skip to main content

Table 1 Associations of let-7e, BRCA1 and Rad51 expression with clinicopathological characteristics of EOC patients

From: Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair

Clinicopathological Features No. of Cases Let-7e expression No.(%) No. of Cases BRCA1 expression No.(%) Rad51 expression No.(%)
   Low High P Value a   Low High P Value a Low High P Value a
Age at surgery, y
 <50 25 10 (40.0) 15 (60.0) 1 26 11 (42.3) 15 (57.7) 0.800 11 (42.3) 15 (57.7) 0.126
 ≥50 40 15 (37.5) 25 (62.5)   39 19 (48.7) 20 (51.3)   25 (64.1) 14 (35.9)  
Histological subtypes
 Serous 53 22 (41.5) 31 (58.5) 0.344 52 24 (46.2) 28 (53.8) 1 27 (51.9) 25 (48.1) 0.355
 Others 12 3 (25.0) 9 (75.0)   13 6 (46.2) 7 (53.8)   9 (69.2) 4 (30.8)  
FIGO stage
 I–II 17 5 (29.4) 12 (70.6) 0.563 18 9 (50.0) 9 (50.0) 0.784 13 (72.2) 5 (27.8) 0.104
 III–IV 48 20 (41.7) 28 (58.3)   47 21 (44.7) 26 (55.3)   23 (48.9) 24 (51.1)  
Tumor categories
 Type I 15 3 (20.0) 12 (80.0) 0.133 16 8 (50.0) 8 (50.0) 0.778 11 (68.7) 5 (31.3) 0.258
 Type II 50 22 (44.0) 28 (56.0)   49 22 (44.9) 27 (55.1)   25 (51.0) 24 (49.0)  
Chemotherapy response
 Sensitive 43 8 (18.6) 35 (81.4) <0.0001 46 26 (56.5) 20 (43.5) 0.013 33 (71.7) 13 (28.3) <0.0001
 Resistant 22 17 (77.3) 5 (22.7)   19 4 (21.1) 15 (78.9)   3 (15.8) 16 (84.2)  
  1. EOC epithelial ovarian cancer, FIGO International Federation of Gynecology and Obstetrics
  2. a Fisher exact test